September 30, 2016 12:35 PM EDT
R&D

Fol­low­ing lethal tox re­port, Boehringer scraps plans for high-speed de­vel­op­ment, kills $730M Han­mi deal

John Carroll

Editor & Founder

Boehringer-In­gel­heim de­cid­ed to abrupt­ly wash its hands of a $730 mil­lion can­cer drug col­lab­o­ra­tion with Han­mi af­ter a South Ko­re­an min­istry linked the ther­a­py to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lykos’ MD­MA-as­sist­ed ther­a­py stum­bles at ad­comm amid ques­tions about study, safe­ty and abuse

What the first four par­tic­i­pants for FDA's Op­er­a­tion Warp Speed for rare dis­eases are tack­ling

Ex­clu­sive: In­spired by Spin­raza, start­up rais­es $25M for can­cer drug tar­gets cre­at­ed by al­ter­na­tive RNA splic­ing

No­vo Hold­ings’ head of Asia on in­vest­ing in ‘Chi­na for Chi­na,’ and stay­ing out of biotech (for now)

UK's NICE rec­om­mends Lil­ly's Zep­bound for weight loss

At AS­CO: big read­outs, rev­enue ques­tions, and the ups and downs of AD­Cs

A service from the Financial Times